Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital. | Read the press release »

Partnering to Deliver Cell Therapies for Patients

Kincell Bio is a leading cell therapy CDMO offering clients a personalized and expert-driven approach to process development and manufacturing from early clinical to pivotal supply and commercial launch.

Why Kincell?

A spectrum of CDMO services

Kincell supports the continuum of cell therapy CMC development and manufacturing from early, to late phase, clinical product supply.

Expert analytical testing to ensure the quality, consistency, and potency of your product.

Analytical Development

Phase-appropriate development strategies to ensure right-first-time performance.

Process Development

Efficient manufacturing across all stages of development to supply products with the highest quality standards.

GMP Manufacturing

Delivering Cell Therapies for Patients

Watch our presentation from the Outsourced Pharma Capacity Update 2025 to learn how our integrated CDMO solutions accelerate immune cell therapy development from early-phase to commercial readiness.

Upcoming Event

Meet our team at Bio International

We’re excited to be attending the BIO International Convention from June 16–19 in Boston! If you’re developing cell therapies, let’s connect. Come learn how we can support your program with flexible, expert-driven solutions from early development through commercial readiness. Looking forward to seeing you in Boston!

Book a Meeting

Let’s get started

Learn how Kincell can accelerate your time to market.

1622 NW 55th Place
Gainesville, FL 32653

20 TW Alexander Dr, Suite 130
RTP, NC 27703

contactus@kincellbio.com